SIRT1在肺腺癌组织中的表达及临床意义

发布时间：2019-01-17 21:14

【摘要】：目的探讨肺腺癌组织中SIRT1的表达水平与临床病理参数、EGFR扩增及预后的关系,阐明其在肺腺癌发生发展中的可能作用。方法采用免疫组织化学染色法检测肺腺癌组织芯片中75例癌组织及配对癌旁正常组织中SIRT1的表达。并采用探针杂交方法检测肺腺癌组织中人内皮生长因子受体(epidermal growth factor receptor,EGFR)的扩增水平,采用χ2检验分析SIRT1表达水平、EGFR扩增水平分别与临床病理特征的关系;采用Kaplan-Meier法及Log-rank检验分SIRT1表达水平、EGFR扩增水平与总生存期(overall survival,OS)的关系;拟合多因素Cox模型,采用风险比(hazard ratio)评价不同临床指标与死亡风险的相关性,采用相关性分析EGFR扩增水平与SIRT1表达水平相关性。结果肺腺癌组织中SIRT1的表达高于癌旁正常组织(H-score评分均值分别为260和113,P0.001);肺腺癌组织中SIRT1的表达水平和肺腺癌患者的性别、年龄、淋巴结转移、肺腺癌亚型、远处转移、TNM分期无显著相关(P值分别为0.201,0.232,0.318,0.377,0.245,1.000,0.216),而与病理分级显著相关(P=0.029)。肺腺癌组织中EGFR扩增水平和患者的性别、年龄、病理分级、远处转移、TNM分期、肺腺癌亚型无显著相关性(P值分别为0.608,0.274,0.588,0.275,0.317,0.449),而与淋巴结转移显著相关(P=0.004)。单因素和多因素回归分析均显示SIRT1高表达组肺腺癌患者的死亡风险较低表达组显著增加(HR=3.991,95%CI:1.411~11.288,P=0.009;HR=4.388,95%CI:1.192~16.155,P=0.026)。EGFR扩增阳性与阴性组死亡风险无明显差异(HR=1.452,95%CI:0.835~1.997,P=0.2446;HR=1.896,95%CI:0.505~3.726,P=0.443)。EGFR扩增水平与SIRT1表达水平无明显相关性(r=0.223,P=0.278)。结论肺腺癌中SIRT1表达与病理分级显著相关,SIRT1高表达提示肺腺癌预后较差。SIRT1表达水平是肺腺癌患者预后判断的独立危险因素。EGFR扩增水平与SIRT1表达水平之间无显著相关性。
[Abstract]:Objective to investigate the relationship between the expression of SIRT1 and clinicopathological parameters, EGFR amplification and prognosis in lung adenocarcinoma, and to elucidate its possible role in the development of lung adenocarcinoma. Methods Immunohistochemical staining was used to detect the expression of SIRT1 in 75 cases of lung adenocarcinoma tissue microarray and matched normal tissues. The amplification level of human endothelial growth factor receptor (epidermal growth factor receptor,EGFR) in lung adenocarcinoma was detected by probe hybridization. The expression of SIRT1 and the relationship between EGFR amplification and clinicopathological characteristics were analyzed by 蠂 2 test. The expression level of SIRT1 and the relationship between EGFR amplification and total survival (overall survival,OS) were detected by Kaplan-Meier and Log-rank test. The risk ratio (hazard ratio) was used to evaluate the correlation between different clinical indexes and death risk, and the correlation between EGFR amplification level and SIRT1 expression level was analyzed by correlation analysis. Results the expression of SIRT1 in lung adenocarcinoma tissues was higher than that in adjacent normal tissues (the mean H-score scores were 260 and 113 P0.001, respectively). There was no significant correlation between the expression of SIRT1 in lung adenocarcinoma and sex, age, lymph node metastasis, subtype, distant metastasis and TNM stage of lung adenocarcinoma (P = 0.201 0.2320.3180.3770.2451.0000.216). There was a significant correlation between the pathological grade and the pathological grade (P < 0.029). There was no significant correlation between EGFR amplification level and sex, age, pathological grade, distant metastasis, TNM stage and subtype of lung adenocarcinoma (P = 0.6080.274 / 0.2750.317170.449, respectively). There was a significant correlation with lymph node metastasis (P0. 004). Univariate and multivariate regression analysis showed that the death risk of lung adenocarcinoma patients with high expression of SIRT1 was significantly higher than that of low expression group (HR=3.991,95%CI:1.411~11.288,P=0.009;). There was no significant difference in the risk of death between HR=4.388,95%CI:1.192~16.155,P=0.026). EGFR amplification positive and negative groups (HR=1.452,95%CI:0.835~1.997,P=0.2446;). There was no significant correlation between the HR=1.896,95%CI:0.505~3.726,P=0.443). EGFR amplification level and the SIRT1 expression level (r = 0.223 P = 0.278). Conclusion there is a significant correlation between the expression of SIRT1 and pathological grade in lung adenocarcinoma. The high expression of SIRT1 suggests that the prognosis of lung adenocarcinoma is poor. The expression of SIRT1 is an independent risk factor for prognosis of lung adenocarcinoma. There is no significant correlation between EGFR amplification level and SIRT1 expression level.
【学位授予单位】：苏州大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R734.2

【相似文献】